Shares of Sunshine Biopharma, Inc. (SBFM) soared over 70% on Wednesday morning after the company announced positive results of mRNA therapy for cancer.
SBFM is currently trading at $3.5906, up $1.5006 or 71.4776%, on a huge volume of 36.5 million shares, above average volume of 71 thousand, on the Nasdaq. The stock opened its trading at $3.3000 after closing Tuesday at $2.0900. The stock has traded between $1.9000 and $248.0000 in the past 52-week period.
Sunshine Biopharma announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma.
Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.